Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient

Seyahi E., Ozdogan H., Masatlioglu S., Yazici H.

Clinical and Experimental Rheumatology, cilt.20, 2002 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20
  • Basım Tarihi: 2002
  • Dergi Adı: Clinical and Experimental Rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Colchicine is the treatment of choice in familial Mediterranean fever (FMF) both for attacks and for prevention of secondary amyloidosis. The overall non-responder rate varies from 5-10 to 40%. Thalidomide is known to blunt the acute phase response. We report the efficacy of the addition of thalidomide to colchicine in controlling the febrile attacks and acute phase response in a patient with FMF resistant to 2 mg colchicine per day.